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Introduction: Portal venous thrombosis is a life-threatening cause of abdominal pain. In younger 
patients, heritable thrombophilias, pregnancy, tobacco use, and oral contraceptives are associated.
Case Report: A 26-year-old woman prescribed contraceptive vaginal ring presented with abdominal 
pain and was diagnosed with an extensive portal venous thrombosis. Management included heparin 
and later an oral anticoagulant with good short-term outcome.
Discussion: Women using hormonal contraception are approximately four times more likely to 
develop thromboembolism. Risk of thromboembolism is similar between users of intravaginal and 
oral contraceptives.
Conclusion: Portal venous thrombosis must be considered in women presenting with abdominal 
pain who are prescribed hormonal contraceptives, including intravaginal forms. [Clin Pract Cases 
Emerg Med. 2020;4(2):263–266.]    
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INTRODUCTION
Abdominal pain continues to be one of the most 
common complaints evaluated in the emergency department 
(ED) in the United States. According to Meltzer et al 
abdominal pain comprised approximately 23 million visits 
to the ED in one year.1 Comparatively, mesenteric venous 
thrombosis is a relatively rare condition, accounting for 
less than 0.02% of all hospital admissions.2,3 The mean 
age of mesenteric thrombosis is 45-60 years, with a large 
proportion occurring in the sixth and seventh decades.2-4 
In younger individuals, mesenteric thrombosis is often 
associated with the following: heritable thrombophilias (e.g., 
protein C or protein S deficiency);  acquired thrombophilias 
(e.g., pregnancy or medication use, commonly oral 
contraceptives); intra-abdominal causes (e.g., cirrhosis or 
trauma); or idiopathic causes.2 This is a case of a 26-year-
old woman who presented to the ED with right upper 
quadrant abdominal pain due to extensive thrombus within 
the superior mesenteric, main portal, distal splenic, and 
intrahepatic portal veins. After extensive diagnostic testing, 
the only identified thrombotic risk factor was the use of an 
etonogestrel/ethinyl estradiol vaginal ring (NuvaRing). 
CASE REPORT
A 26-year-old woman without medical history presented 
to the ED due to abdominal pain for approximately 12 
hours. The patient reported no tobacco use, and her only 
prescribed medication was the etonogestrel/ethinyl estradiol 
intravaginal ring. The patient had been evaluated earlier in 
the day at an urgent care facility; the urgent care provider 
then sent the patient to the ED for an apparent abnormal 
urinalysis (UA). In the ED, she was complaining of 
mid-epigastric and right upper quadrant abdominal pain 
along with continued nausea. She also noted back pain, a 
headache, and bilateral upper extremity numbness since that 
morning. She noted her bilateral upper extremity numbness 
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What do we already know about this clinical 
entity? 
Portal venous thrombosis is well studied in the 
literature and has known risk factors such as 
age, heritable and acquired coagulopathies, and 
idiopathic causes.
What makes this presentation of disease 
reportable? 
This patient’s only risk factor predisposing 
her to a large portal venous thrombosis was 
the use of an etonogestrel/ ethinyl estradiol 
vaginal ring contraceptive.
What is the major learning point? 
Emergency physicians should be cognizant 
that all forms of contraception with exogenous 
hormones expose patients to a risk of 
significant thrombosis.
How might this improve emergency medicine 
practice? 
Practitioner awareness regarding thrombotic 
risk related to all forms of hormonal 
contraception, including intravaginal forms, 
may assist in accurate diagnosis.
and headache had become intermittent. She denied any 
associated diarrhea, constipation, dysuria, fever, chills, 
recent travel, or trauma. 
The patient’s vital signs included the following: 
temperature 98.0º Fehrenheit; heart rate 76 beats per minute; 
respirations 18 breaths per minute; blood pressure 129/53 
millimeters of mercury; and pulse oximetry 98% on room 
air. On physical exam, she exhibited moderate tenderness to 
palpation of the right upper quadrant and epigastric area. The 
remainder of the physical exam was unremarkable. 
There were no considerable lab abnormalities except 
for “small” bilirubin noted on the UA. Urine pregnancy 
test was negative. The patient had a computed tomography 
(CT) of the abdomen/pelvis with intravenous (IV) contrast, 
which demonstrated an extensive thrombus within the 
superior mesenteric vein, extending into the main portal 
vein, intrahepatic portal veins, and distal splenic vein (Image 
1). She was administered IV heparin 5800 units bolus and a 
continuous IV heparin infusion of 18 units per kilogram per 
hour. She was then transferred to a tertiary care center.
At the tertiary care center, the patient was maintained 
on the heparin infusion until she was later transitioned to 
rivaroxaban. The patient underwent extensive hematologic 
testing including the following: protein C; protein S; anti-
thrombin III; alpha fetoprotein, homocysteine; factor 5 
gene mutation; prothrombin gene mutation; anti-cardiolipin 
antibody IgG and IgM by ELISA; anti-beta2-GP I antibody; 
JAK2 V617F mutation; and mutation in exon 12 of JAK2. 
No abnormalities were detected. The patient also had 
normal venous Doppler studies of the bilateral upper and 
lower extremities. Ultimately she was discharged home 
on hospital day 3 on rivaroxaban 15 milligrams twice 
daily with hematology follow-up and discontinuation of 
hormonal contraception. 
DISCUSSION
The clinical presentation, diagnosis, and management 
of portal and mesenteric venous thrombosis has been 
thoroughly investigated in the literature. In the acute 
setting, mesenteric venous thrombosis most commonly 
causes abdominal pain in 91-100% of cases.5 The test of 
choice for the diagnosis of mesenteric venous thrombosis 
is a contrast-enhanced CT.6 Laboratory testing is not 
especially helpful as most tests do not correlate specifically 
to the diagnosis of mesenteric thrombus.5 Once the 
diagnosis is established, treatment includes resolving the 
current thrombus and preventing further thrombotic events. 
Anticoagulation with low-molecular-weight heparin as 
soon as the diagnosis is made has been shown to improve 
survival.7 Transitioning to an oral anticoagulant is then 
performed. According to the 2016 CHEST guidelines, 
patients with venous thromboembolism should be 
treated for a minimum of six months. These guidelines 
are commensurate with those set forth by the European 
Image. Axial image of abdominal/pelvis computed tomography with 
contrast demonstrates the thrombus, indicated by the black arrows, in 
the superior mesenteric vein and extending toward the splenic vein.
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Association for the Study of the Liver, specifically for 
mesenteric thrombus.8,9 After the acute thrombotic event 
has been stabilized, the patient requires hematologic testing 
to assess for prothrombotic diseases.5
Women using hormonal contraception are approximately 
four times more likely to develop venous thromboembolism 
compared to women not prescribed hormonal contraception.10 
Studies report the association between hormonal contraception 
and increased risk of thromboembolism is related to 
the alteration of procoagulant factors and endogenous 
anticoagulant proteins. The estrogen components of hormonal 
contraception seem to cause an increase in the procoagulant 
factors II, VII, VIII, X and fibrinogen, and a decrease in 
antithrombin and tissue factor pathway inhibitor activity.11,12 
It should be noted that the formulation, administration route, 
dose, and progesterone type (in combined formulations), all 
affect the overall risk of thrombosis.11,12 There is a general 
misnomer that non-oral forms of hormonal contraception (e.g., 
etonogestrel/ethinyl estradiol vaginal ring) have a lower risk 
of thrombotic events compared to oral contraception. 
The Transatlantic Active Surveillance on 
Cardiovascular Safety of NuvaRing study, published in 
2013, did not specifically report episodes of mesenteric 
venous thrombosis, although it did report that episodes 
of venous and arterial thromboembolism were similar 
between clinical users of intravaginal contraceptive rings 
and oral contraceptives.13 While mesenteric thrombosis 
associated with intravaginal contraception is rare, two 
similar cases have been reported in the literature.14,15 
In addition, when obtaining medication history from 
patients, non-oral medications can often be missed or 
discounted by clinicians. Although research is somewhat 
limited, the etonogestrel/ethinyl estradiol vaginal ring does 
appear to have the same amount of cardiovascular risk 
associated with its use as its well-studied counterpart, oral 
contraceptive pills.13 
CONCLUSION
This case highlights that women without known, primary 
thrombotic risk factors can still suffer major, life-threatening 
thrombosis when using hormonal contraception, regardless 
of form. The diagnosis of mesenteric and portal venous 
thrombosis must be considered in women presenting with 
abdominal pain who are prescribed hormonal contraceptives, 
including intravaginal forms.
The documented attestation from the authors that their 
institution requires neither Institutional Review Board approval, 
nor patient consent for publication of this case report has been 
obtained and filed.
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